Every 424B that OneMedNet Corp (ONMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.
OneMedNet Corporation (ONMD) filed a prospectus supplement registering up to 11,680,535 shares of common stock and incorporating its Form 10‑Q for the quarter ended June 30, 2026.
For Q2 2026, revenue was $292 thousand (up from $155 thousand a year earlier), driven by higher data delivery revenue, but the company posted a net loss of $2,172 thousand and a six‑month net loss of $4,625 thousand. Cash and cash equivalents were $358 thousand against $4,882 thousand of total liabilities and a stockholders’ deficit of $3,518 thousand, and management states there is substantial doubt about the company’s ability to continue as a going concern.
ONMD no longer holds Bitcoin, having liquidated prior crypto holdings in 2026. Liquidity has recently been supported by related‑party equity subscriptions and a $25.0 million Standby Equity Purchase Agreement, followed post‑quarter by a new 2026 SEPA of the same size. The company received a Nasdaq notice on April 14, 2026 for not meeting the $1.00 minimum bid price and reports ongoing material weaknesses in internal control over financial reporting.
OneMedNet Corporation (ONMD) filed a prospectus supplement for a mixed offering registering a primary sale of up to 11,500,000 shares of common stock and a secondary resale of up to 28,152,560 shares. The supplement incorporates the company’s Form 10-Q for the quarter ended June 30, 2026.
For Q2 2026, revenue was $0.3 million, up 88% year over year, driven by higher data delivery revenue as the business shifts to its real-world data platform, while legacy subscription revenue from the BEAM platform has ended. The company reported a net loss of about $2.2 million for the quarter and $4.6 million for the first half of 2026.
As of June 30, 2026, cash was approximately $0.4 million with total assets of about $1.4 million versus liabilities of $4.9 million, resulting in a stockholders’ deficit of roughly $3.5 million. Management states that these conditions raise substantial doubt about the ability to continue as a going concern and is relying on equity financing, including related-party subscriptions and standby equity purchase arrangements, to fund operations.
OneMedNet Corporation is registering up to 11,680,535 shares of Common Stock for resale by existing holders. This includes up to 8,500,000 shares issuable under a $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville and shares previously issued to directors Dr. Thomas Kosasa and Dr. Jeffrey Yu (including stock issued in lieu of cash compensation).
The company will not receive any proceeds from these resales, though it could receive cash in the future from issuing SEPA shares. As of June 30, 2026, 56,952,652 shares were outstanding, and the registered shares equal about 18.1% of that amount, highlighting potential dilution and overhang. A 19.99% SEPA “Exchange Cap” (11,386,834 shares) and a 4.99% ownership limit apply absent stockholder approval.
OneMedNet reports net losses of $2.8 million in 2025 and $10.1 million in 2024 with an accumulated deficit of $104.4 million, and its auditors raise substantial doubt about going concern. The company also faces Nasdaq minimum bid-price noncompliance, extensive business and regulatory risks, and additional volatility from holding bitcoin.
OneMedNet Corporation is offering up to 11,500,000 shares of common stock in a primary offering. This prospectus supplement (No. 4) to the Prospectus (S-1, Registration No. 333-276130) also registers the resale of up to 28,152,560 shares by selling stockholders.
The supplement attaches the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and updates the Prospectus. Key near-term facts disclosed include shares outstanding of 54,433,407 as of May 12, 2026, a net loss of $2.45 million for the three months ended March 31, 2026, a cash balance of $233,000, and a Bitcoin holding with a reported fair value of $66,000 as of March 31, 2026. The filing also discloses a SEPA facility allowing up to $25.0 million of Common Stock sales subject to certain limitations and conditions.
OneMedNet Corporation is offering up to 11,500,000 shares of Common Stock in a primary offering and registering up to 28,152,560 shares of Common Stock for resale. This prospectus supplement (dated March 30, 2026) updates the prospectus dated July 24, 2025 and attaches the company’s Form 10-K for the year ended December 31, 2025.
The supplement states the company is an emerging growth company and highlights that investors should review the Prospectus' Risk Factors. The registrant reported 52,196,729 shares outstanding as of March 27, 2026, and the supplement incorporates the audited annual report information into the registration statement.
OneMedNet Corporation filed Prospectus Supplement No. 2 to its Form S-1, registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. The supplement updates the prospectus dated July 24, 2025 and attaches the company’s Q3 2025 Form 10-Q for the quarter ended September 30, 2025.
The company is an emerging growth company and notes that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the prospectus. As context, shares outstanding were 51,005,205 as of November 7, 2025. The supplement must be read together with the base prospectus, and neither the SEC nor any state commission has approved or disapproved the securities.